Drug
Smp3124lp
Smp3124lp: highest development phase Phase 1/2, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SMP3124LP NCT06526819 | Phase 1/2 | Solid Tumor |
Latest
No recent events.
Follow Smp3124lp on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.